Nephrology and Urology

  • AKI seen in 64% of children hospitalized with diabetic ketoacidosis

    on March 13th, 2017
    FROM JAMA PEDIATRICS A high proportion of children with type 1 diabetes who are hospitalized for diabetic ketoacidosis (DKA) develop acute kidney injury (AKI), according to results from a study. Researchers reviewing records from a Canadian hospital found that in a cohort of 165 children hospitalize[...]
  • No benefit from adjuvant sunitinib or sorafenib for clear cell renal cancer

    on March 9th, 2017
    FROM JAMA ONCOLOGY Adjuvant sunitinib or sorafenib show no significant advantages in disease-free or overall survival over placebo in patients with high-risk clear cell renal cancer, according to secondary analysis of data from the ASSURE trial. The primary analysis of data from the ASSURE trial, wh[...]
  • Voclosporin linked to threefold increase in lupus nephritis remission

    on March 6th, 2017
    Treatment with the investigational calcineurin inhibitor voclosporin is associated with a significant, threefold-higher rate of complete remission for lupus nephritis, compared with the current standard of care, according to 48-week data from the AURA-LV (Aurinia Urinary Protein Reduction Active–L[...]
  • Chemo gives no boost to ADT for patients with localized prostate cancer

    on March 1st, 2017
    FROM THE GENITOURINARY CANCERS SYMPOSIUM Mitoxantrone plus prednisone (MP) added to androgen deprivation therapy (ADT) does not improve outcomes in patients with clinically localized prostate cancer, according to the results of a large long-term multicenter clinical trial. At a follow-up time of alm[...]
  • ‘Strong evidence’ links obesity to cancers

    on March 1st, 2017
    FROM BMJ There is strong evidence linking adiposity to esophageal adenocarcinoma, multiple myeloma, and cancer of the colon, rectum, biliary tract, pancreas, endometrium, kidney, and postmenopausal breast, according to the authors of an umbrella review published in the Feb. 28 edition of the BMJ. [...]
  • Genomic differences seen in mRCC during first- and second-line therapy

    on February 28th, 2017
    AT THE GENITOURINARY CANCERS SYMPOSIUM ORLANDO (FRONTLINE MEDICAL NEWS) – In the largest assessment to date of circulating tumor DNA (ctDNA) in patients with metastatic renal cell carcinoma (mRCC), the majority of patients were found to have clinically relevant genomic alterations. The most freque[...]
  • New significantly mutated genes detected in prostate cancer

    on February 23rd, 2017
    FROM THE GENITOURINARY CANCERS SYMPOSIUM A new large study has identified 78 significantly mutated genes (SMGs) and has enlarged the genetic landscape of prostate cancer. In addition, 37 genes that were not previously reported as SMGs in prostate cancer and 23 that were not previously identified as [...]
  • Three signs predict hypercalcemic crisis in hyperparathyroid patients

    on February 22nd, 2017
    AT THE ACADEMIC SURGICAL CONGRESS LAS VEGAS (FRONTLINE MEDICAL NEWS) – A triad of signs – elevated serum calcium, elevated parathyroid hormone, and a history of kidney stones – can predict hypercalcemic crisis among patients with hyperparathyroidism, a study showed. Patients who present with t[...]
  • No AR in CTCs linked with better survival in advanced prostate cancer

    on February 17th, 2017
    FROM THE GENITOURINARY CANCERS SYMPOSIUM The presence and amount of full-length androgen receptor biomarker detected in the circulating tumor cells of people with metastatic castration-resistant prostate cancer can inform prognosis, a prospective study reveals. Investigators report significant diffe[...]
  • Survival gains with pembrolizumab in urothelial cancer

    on February 17th, 2017
    FROM THE GENITOURINARY CANCERS SYMPOSIUM Treatment with checkpoint inhibitor pembrolizumab is associated with significant gains in overall survival among patients with treatment-refractory advanced urothelial carcinoma, according to new research. Data from the KEYNOTE-045 trial was presented simulta[...]
  • RNA-based biopsy test bests NCCN risk stratification for PC prognosis

    on February 17th, 2017
    AT THE GENITOURINARY CANCERS SYMPOSIUM ORLANDO (FRONTLINE MEDICAL NEWS) – A genetic assay for prostate cancer typically used after radical prostatectomy could be used earlier, at the time of diagnostic biopsy testing, to classify patients as low, intermediate, and high risk for metastasis and dise[...]
  • Clinical benefit persists for some with mRCC after stopping immune checkpoint blockade

    on February 15th, 2017
    FROM THE 2017 GENITOURINARY CANCERS SYMPOSIUM ORLANDO (FRONTLINE MEDICAL NEWS) – Some people with advanced kidney cancer who respond to immune checkpoint inhibitor therapy and subsequently stop because of immune-related adverse events may continue to see a clinical benefit for 6 months or longer, [...]
  • Antibiotic use may hamper checkpoint inhibitors for mRCC

    on February 14th, 2017
    FROM THE GENITOURINARY CANCERS SYMPOSIUM Antibiotics may hamper the effectiveness of immune checkpoint inhibitors for patients with metastatic renal cell carcinoma, according to a small, retrospective study. Using antibiotics within 1 month of starting a checkpoint inhibitor was associated with sign[...]
Back to top